Importantly, our study sets a remarkable example of cancer plasticity that underlies melanoma primary resistance to drug therapies: upon BRAFi treatment, the resistance is accompanied by MAPK pathway activation, which triggers cell cycle progression and CDK2 activation (Lents et al, 2002). This evidence concerns the gene CDK2 and melanoma.